12:00 AM
Apr 22, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

XenoPort, GlaxoSmithKline sales and marketing update

GlaxoSmithKline said it has experienced "spot outages" of Horizant gabapentin enacarbil, which is approved to treat restless legs syndrome (RLS) and to manage postherpetic neuralgia (PHN), due to undisclosed manufacturing delays. GSK said certain patients may not be able to have prescriptions filled in the near term and...

Read the full 228 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >